tbResList Print — Matr Matrine

Filters: qv=322, qv2=%, rfv=%

Product

Matr Matrine
Description: <p><b>Matrine</b> — a naturally occurring tetracyclic quinolizidine alkaloid found predominantly in <i>Sophora flavescens</i> and related <i>Sophora</i> species, including <i>Sophora tonkinensis</i>. It is a plant-derived bioactive small molecule rather than an approved anticancer drug. Common abbreviations include Mat and MT. Matrine has broad anti-inflammatory, antifibrotic, neuroprotective and preclinical anticancer activities. Cancer studies consistently identify apoptosis, PI3K/AKT/mTOR suppression, Wnt/β-catenin inhibition, metabolic suppression, inhibition of invasion/EMT and context-dependent ROS-mediated cell death as important actions. More recent work also supports ferroptosis through pathways involving GPX4 and β-catenin/TCF7L2. Matrine should be distinguished from oxymatrine and from Compound Kushen Injection, which contains multiple constituents and has substantially more human clinical data.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of programmed cancer-cell death, particularly mitochondrial/caspase-dependent apoptosis through ↓ Bcl-2/Bax ratio, ↑ caspase-3/9 activity and suppression of survival proteins.</li>
<li>Suppression of PI3K/AKT/mTOR signaling, reducing cancer-cell survival, proliferation and growth while contributing to apoptosis and autophagy.</li>
<li>Suppression of Wnt/β-catenin signaling, including direct disruption of β-catenin/TCF7L2 signaling in some models, thereby reducing proliferation, metastasis and GPX4-mediated ferroptosis resistance.</li>
<li>Suppression of tumor glycolysis and the Warburg phenotype through targets including HK2 and, in recent TNBC work, ENO1-associated glycolytic enzyme complexes.</li>
<li>Inhibition of EMT, migration, invasion and metastasis through modulation of PTEN/AKT, β-catenin, E-cadherin, vimentin, MMP-2 and MMP-9.</li>
<li>Induction of ROS-mediated stress signaling in susceptible cancer cells; ROS can activate p38 and contribute to apoptosis, autophagy and ferroptosis. This effect is strongly model- and concentration-dependent.</li>
<li>Induction of ferroptosis in selected cancer models through ↓ GPX4, ↑ lipid peroxidation and, depending on tumor type, Piezo1/Ca²⁺ or β-catenin/TCF7L2 signaling.</li>
<li>Anti-angiogenic activity through suppression of VEGF/VEGFR signaling.</li>
<li>Chemosensitization in preclinical models, including increased cisplatin sensitivity through suppression of glycolysis/lactylation and DNA-repair-associated resistance mechanisms.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Oral matrine has relatively unfavorable and formulation-dependent pharmacokinetics. Rat studies report absolute oral bioavailability of approximately 17%, although botanical matrices can substantially alter absorption and disposition. A small human pharmacokinetic study using a multi-component botanical preparation detected systemic matrine and reported an approximately 10-hour plasma terminal half-life, but this cannot be directly extrapolated to purified matrine dosing. Low oral exposure, rapid disposition in several animal studies and toxicity are important constraints motivating nanoparticle, liposomal and other delivery approaches.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many cancer-cell studies use matrine in the high-micromolar to millimolar range, frequently approximately 0.1–2 mM or higher. These concentrations are substantially above exposures that can confidently be assumed achievable following conventional oral administration. Consequently, direct translation of many in-vitro anticancer effects to oral supplementation is uncertain. Newer studies identifying direct targets at lower concentrations improve mechanistic credibility but do not yet establish a clinically achievable anticancer exposure.<br>
-**can be heptotoxic, but selenium may alleviate the toxicity.
</p>

<p><b>Clinical evidence status:</b> Predominantly preclinical for purified matrine as an anticancer agent. Cell-culture and animal xenograft evidence is extensive, but there is no established Phase I/II oncology development program demonstrating efficacy of purified matrine. Human randomized evidence frequently cited for “matrine” actually concerns Compound Kushen Injection, a multi-component <i>Sophora flavescens</i>-based preparation used adjunctively with chemotherapy in China; those results cannot be attributed specifically to matrine. Matrine is therefore best classified as a preclinical/investigational anticancer compound rather than an established adjunct cancer therapy. Hepatotoxicity and neurotoxicity are important dose-limiting safety concerns.</p>


<h3>Matrine Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Apoptosis / Bcl-2 / Bax / Caspases</td>
<td>↓ Bcl-2/Bax; ↑ Bax; ↑ caspase-3/9; ↑ apoptosis</td>
<td>Lower cytotoxicity reported in some comparative cell models</td>
<td>Programmed tumor-cell death</td>
<td>One of the most reproducible matrine anticancer phenotypes across tumor types.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K / AKT / mTOR</td>
<td>↓ PI3K; ↓ p-AKT; ↓ mTOR signaling</td>
<td>Context-dependent</td>
<td>↓ survival and proliferation; ↑ apoptosis/autophagy</td>
<td>Central signaling axis supported in lung, breast, liver and other cancer models.</td>
</tr>
<tr>
<td>3</td>
<td>Wnt / β-catenin / TCF7L2</td>
<td>↓ β-catenin signaling; ↓ β-catenin/TCF7L2 complex</td>
<td>Not adequately characterized</td>
<td>↓ proliferation and metastasis; ↑ ferroptosis</td>
<td>Recent evidence supports β-catenin as a direct matrine target in TNBC; inhibition can reduce GPX4 transcription.</td>
</tr>
<tr>
<td>4</td>
<td>Glycolysis / Warburg Effect / HK2 / ENO1</td>
<td>↓ HK2; ↓ ENO1-associated glycolytic complex; ↓ glycolytic flux; ↓ lactylation</td>
<td>Not adequately characterized</td>
<td>Metabolic suppression and apoptosis</td>
<td>HK2 suppression is established in myeloid leukemia. Recent TNBC evidence identifies ENO1 as a direct target relevant to cisplatin resistance.</td>
</tr>
<tr>
<td>5</td>
<td>EMT / PTEN / AKT / MMP-2 / MMP-9</td>
<td>↑ PTEN; ↓ AKT; ↑ E-cadherin; ↓ vimentin; ↓ MMP-2/9</td>
<td>Not adequately characterized</td>
<td>↓ migration, invasion and metastasis</td>
<td>Supported across breast, hepatocellular, cervical and colorectal cancer models.</td>
</tr>
<tr>
<td>6</td>
<td>Ferroptosis / GPX4 / Lipid Peroxidation</td>
<td>↓ GPX4; ↑ Fe²⁺; ↑ lipid ROS; ↑ ferroptosis</td>
<td>Uncertain</td>
<td>Iron-dependent cancer-cell death</td>
<td>Demonstrated in cervical cancer and TNBC models. Mechanism is tumor-context dependent.</td>
</tr>
<tr>
<td>7</td>
<td>ROS / p38 Stress Signaling</td>
<td>↑ ROS; ↑ p38 activation; ↑ apoptosis</td>
<td>Variable; antioxidant effects reported in non-cancer disease models</td>
<td>Oxidative-stress-mediated cell death</td>
<td>ROS scavenging with NAC can attenuate matrine-induced apoptosis in susceptible cancer models. ROS direction is highly context-dependent outside cancer.</td>
</tr>
<tr>
<td>8</td>
<td>Ca²⁺ / Piezo1 / Ferroptosis</td>
<td>↑ Piezo1; ↑ Ca²⁺ influx; ↑ lipid peroxidation; ↑ ferroptosis</td>
<td>Not established</td>
<td>Ferroptotic cell death</td>
<td>Mechanistically demonstrated in cervical cancer; should be considered a contextual rather than universal matrine mechanism.</td>
</tr>
<tr>
<td>9</td>
<td>Autophagy / AMPK / AKT / mTOR</td>
<td>↑ LC3-II; ↑ Beclin-1; ↓ p62; ↑ autophagy</td>
<td>Context-dependent</td>
<td>Stress response and tumor growth inhibition</td>
<td>Autophagy may contribute to or oppose apoptosis depending on model and treatment conditions.</td>
</tr>
<tr>
<td>10</td>
<td>VEGF / VEGFR Angiogenesis</td>
<td>↓ VEGF; ↓ VEGFR signaling; ↓ microvessel density</td>
<td>Not adequately characterized</td>
<td>↓ tumor angiogenesis</td>
<td>Observed in breast-cancer xenografts and linked with AKT/NF-κB and Wnt/β-catenin modulation.</td>
</tr>
<tr>
<td>11</td>
<td>NF-κB Signaling</td>
<td>Usually ↓ IKKβ / NF-κB activity; context-dependent activation also reported</td>
<td>Context-dependent</td>
<td>↓ survival, inflammation and invasion</td>
<td>Direction is not uniform. In HepG2 cells matrine-induced NF-κB activation appeared protective because NF-κB inhibition increased matrine-induced apoptosis.</td>
</tr>
<tr>
<td>12</td>
<td>Chemosensitization</td>
<td>↑ sensitivity to cisplatin and selected anticancer agents (model-dependent)</td>
<td>Insufficient evidence</td>
<td>Potential reversal of treatment resistance</td>
<td>Recent TNBC work links cisplatin sensitization to direct ENO1 targeting, ↓ glycolysis/lactylation and impaired resistance-associated DNA repair. Primarily preclinical evidence.</td>
</tr>
<tr>
<td>13</td>
<td>Clinical Translation Constraint</td>
<td>High experimental concentrations frequently required</td>
<td>Hepatotoxicity and neurotoxicity possible at excessive exposure</td>
<td>Limits systemic therapeutic window</td>
<td>Low oral bioavailability, uncertain human tumor exposure, formulation dependence and toxicity remain major barriers. Clinical findings with Compound Kushen Injection cannot be attributed specifically to matrine.</td>
</tr>
</tbody>
</table>




<br><br>
<hr>
<br><br>

<p><b>Alzheimer's disease relevance:</b> Matrine has meaningful but entirely preclinical evidence in Alzheimer’s disease models. Reported effects include inhibition of Aβ aggregation, interference with the RAGE/Aβ axis, reduction of Aβ deposition, suppression of microglial activation and NADPH-oxidase-derived oxidative stress, reduction of inflammatory cytokines, and improvement of learning and memory in rodent models. No convincing human therapeutic evidence establishes matrine as an AD treatment.</p>

<p><b>Clinical evidence status:</b> Preclinical only. The strongest evidence consists of cellular Aβ studies and multiple rodent AD models; clinical efficacy, dosing, long-term neurological safety and achievable CNS exposure remain undetermined.</p>


<h3>Matrine in Alzheimer's Disease</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Aβ Aggregation</td>
<td>↓ Aβ42 aggregation; ↑ disaggregation of immature oligomers</td>
<td>↓ amyloid-associated cytotoxicity</td>
<td>Demonstrated in biochemical/cellular systems and supported by reduced Aβ deposition in animal models.</td>
</tr>
<tr>
<td>2</td>
<td>RAGE / Aβ Axis</td>
<td>↓ RAGE/Aβ signaling</td>
<td>↓ Aβ-mediated neuronal injury and inflammation</td>
<td>A prominent mechanism in an AD transgenic-mouse study.</td>
</tr>
<tr>
<td>3</td>
<td>Microglial Activation / Neuroinflammation</td>
<td>↓ microglial activation; ↓ TNF-α; ↓ IL-1β; ↓ IL-6</td>
<td>↓ neuroinflammation</td>
<td>Associated with improved learning and memory in Aβ-induced mouse models.</td>
</tr>
<tr>
<td>4</td>
<td>NADPH Oxidase / ROS</td>
<td>↓ gp91phox; ↓ p47phox; ↓ ROS</td>
<td>↓ oxidative neuronal stress</td>
<td>Notable contrast with the pro-oxidant ROS response reported in several cancer-cell models.</td>
</tr>
<tr>
<td>5</td>
<td>Th17 / Treg Balance</td>
<td>↓ IL-17A; ↓ IL-23; ↓ RORγt; ↑ TGF-β; ↑ IL-35; ↑ Foxp3</td>
<td>Immune modulation</td>
<td>Reported in an Aβ1-42 rat model together with improved cognitive performance.</td>
</tr>
<tr>
<td>6</td>
<td>Clinical Translation Constraint</td>
<td>Human efficacy unknown</td>
<td>Preclinical evidence only</td>
<td>CNS exposure, effective human dose, chronic safety and clinical benefit have not been established.</td>
</tr>
</tbody>
</table>

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress(tgid=1) ⓘ

GPx4↝, 1,   GPx4↓, 3,   GSH↓, 3,   Iron↓, 1,   Iron↑, 1,   i-Iron↑, 1,   lipid-P↑, 3,   MDA↑, 1,   ROS↑, 6,   ROS↓, 1,   SOD↓, 1,   xCT/SLC7A11↓, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 1,   ATP↓, 1,   CAIX/CA9↓, 1,   ENO1↓, 1,   Glycolysis↓, 2,   GSK‐3β↓, 1,   p‑GSK‐3β↓, 1,   HK2↓, 3,   lactateProd↓, 1,   PIP3↑, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 16,   Apoptosis?, 2,   BAX↑, 8,   Bax:Bcl2↑, 1,   Bcl-2↓, 9,   BIM↑, 1,   Casp↑, 2,   cl‑Casp3↑, 4,   Casp3↑, 5,   Casp7↑, 1,   Casp8↑, 1,   cl‑Casp9↑, 1,   Casp9↑, 3,   Cyt‑c↑, 1,   mt-Cyt‑c↓, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 5,   IAP1↓, 2,   MDM2↓, 1,   necrosis↑, 1,   p38↓, 3,   p‑p38↓, 1,   survivin↓, 5,   TumCD↑, 2,   XIAP↑, 1,   XIAP↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 8,   p‑Akt↓, 6,   Cavin3↓, 1,   EGFR↓, 1,   ERK↓, 2,   p‑ERK↓, 1,   IKKα↓, 1,   JAK↓, 1,   JAK2↓, 1,   MEK↓, 1,   mTOR↓, 7,   p‑mTOR↓, 2,   PI3K↓, 7,   p‑PI3K↓, 4,   PTEN↑, 3,   STAT3↓, 3,   p‑STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 1,   cMyc↓, 1,   FOXO1↑, 1,   FOXO1↓, 1,   FOXO3↑, 1,   FOXO3↓, 1,   FOXO4↑, 1,   FOXO4↓, 1,   HES1↓, 1,   JPT1/HN1↓, 1,   LINC01116↓, 1,   miR-10b-5p↓, 1,   miR-182-5p↓, 1,   miR-21↓, 1,   miR-22↑, 1,   miR-592↑, 1,   NR1D2↓, 1,   OCT4↓, 1,   other↝, 1,   PAX2↓, 1,   SOX2↓, 1,   tumCV↓, 4,   tumCV∅, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 1,   Erlin1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 4,   LC3B↑, 1,   LC3B-II↑, 2,   LC3II↑, 1,   p62↓, 4,   TumAuto?, 1,   TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 5,   PARP↑, 1,   PCNA↓, 3,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   CHK1↓, 1,   cycD1/CCND1↓, 1,   Ki-67↓, 1,   P21↑, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EIF4E↓, 1,   JAG1↓, 1,   Ki-67↓, 1,   NOTCH↑, 1,   NOTCH1↓, 1,   Piezo1↑, 2,   TumCG↓, 8,   TumCG?, 1,   TumCP↓, 17,   TumCP?, 1,   Wnt↓, 8,  

Migration(tgid=13) ⓘ

AGRN↓, 1,   E-cadherin↑, 4,   E-cadherin↓, 1,   EMT↓, 6,   ITGB1↓, 1,   MMP14↓, 1,   MMP2↓, 10,   MMP9↓, 11,   MTA1↓, 1,   N-cadherin↓, 2,   Sharpin↓, 1,   Slug↓, 2,   Snail↓, 3,   TumCI↓, 13,   TumCMig↓, 15,   TumMeta↓, 3,   TumPF↓, 1,   uPA↓, 1,   Vim↓, 5,   β-catenin/ZEB1↓, 9,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   VEGF↓, 4,   VEGFR1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCR7↓, 1,   HMGB1↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 3,   p‑p65↓, 1,   TCF7/TCF1↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

GGT/CD224↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

CAXII/CA12↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 2,   ChemoSen↑, 7,   ChemoSen?, 1,   Dose↝, 2,   Dose↓, 1,   Dose?, 1,   eff↓, 2,   eff↑, 1,   MRP1/ABCC1↓, 1,   P-gp/ABCB1↓, 2,   selectivity↑, 1,   Synergy↑, 5,  

Clinical Biomarkers(tgid=22) ⓘ

AFP?, 1,   ALAT↓, 1,   ALB↑, 1,   ALP↓, 1,   AST?, 1,   DBIL↓, 1,   EGFR↓, 1,   IBIL↓, 1,   IL6↓, 1,   TBIL↓, 1,  

Functional Outcomes(tgid=23) ⓘ

antiD↑, 1,   cachexia↓, 2,   chemoP↑, 1,   hepatoP↑, 1,   QoL↑, 1,   toxicity↑, 1,   toxicity↝, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 188

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 4,   Catalase↑, 2,   GPx↑, 2,   GPx4↑, 2,   GPx4↓, 1,   GSH↑, 3,   GSH↓, 1,   HO-1?, 1,   HO-1↓, 1,   HO-1↑, 1,   Iron↓, 1,   Iron↝, 1,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↓, 3,   MDA↑, 1,   NRF2?, 1,   NRF2↑, 2,   NRF2↓, 1,   ROS↓, 7,   ROS↑, 2,   SOD↑, 3,   SOD↓, 1,   xCT/SLC7A11↑, 1,   xCT/SLC7A11↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

HSP60/HSPD1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↓, 1,   ALAT↓, 2,   ALAT↑, 1,   ATP↓, 1,   CYP51/14LDM↑, 1,   glucose↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 2,   BAX↓, 1,   Bcl-2↑, 1,   Casp12↓, 1,   Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↓, 1,   Ferroptosis↓, 2,   Ferroptosis↑, 1,   p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↑, 2,   p‑Akt↑, 1,   ERK↓, 1,   JAK2↑, 1,   JNK↓, 1,   mTOR↑, 2,   PI3K↑, 2,   PROKR1↑, 1,   PROKR2↑, 1,   STAT3↑, 2,   p‑STAT3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HOTAIR↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↓, 1,   CHOP/DDIT3↓, 1,   ER Stress↓, 2,   GRP78/BiP↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,  

Migration(tgid=13) ⓘ

PROK2↑, 1,   TGF-β↓, 1,   α-SMA↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↝, 1,   BBB↑, 1,   CLDN4↑, 1,   IBI↑, 1,   MMP↓, 1,   OCLN↑, 1,   TJ↑, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

HMGB1↓, 3,   ICAM-1↓, 1,   IL17↓, 2,   IL1β↓, 4,   IL23↓, 1,   IL6↓, 5,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 9,   Inflam?, 1,   MyD88↓, 1,   NF-kB↓, 5,   RAGE↓, 2,   SOCS-3↓, 1,   TLR4↓, 1,   TNF-α↓, 6,   TRAF6↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 2,   BChE↓, 2,   BDNF↑, 1,   DHCR7↑, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,   Aβ↓, 2,   BACE/β-secretase↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AHR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   BioAv↓, 1,   Dose↝, 2,   Dose?, 1,   eff↓, 1,   Half-Life↝, 1,   Half-Life↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   ALAT↑, 1,   AST↓, 2,   AST↑, 1,   IL6↓, 5,   RAGE↓, 2,  

Functional Outcomes(tgid=23) ⓘ

Analgesic↑, 3,   antiAll↑, 4,   AntiArt↑, 2,   AntiCan↑, 2,   AntiCan?, 1,   AntiDiabetic↑, 1,   AntiTum↑, 4,   cardioP↑, 2,   cognitive↑, 2,   hepatoP↑, 3,   hepatoP↓, 2,   Learn↑, 3,   Learn?, 1,   memory↑, 4,   memory?, 1,   neuroP↑, 7,   NP/CIPN↓, 1,   RenoP↝, 1,   Stroke↓, 4,   toxicity↝, 3,   toxicity↓, 2,   toxicity↑, 3,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 3,   Bacteria↓, 2,   GutMicro↑, 1,   insect↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 136

Research papers

Year Title Authors PMID Link Flag
2026Matrine targets Enolase 1 and regulates the glycolysis-lactylation axis to enhance cisplatin sensitivity in triple-negative breast cancerLi Lin42424673https://pubmed.ncbi.nlm.nih.gov/42424673/0
2026Matrine enhances RLS3-induced ferroptosis at non-toxic doses in acute myeloid leukemia cells with MLL rearrangementYaonan HongPMC12877362https://pmc.ncbi.nlm.nih.gov/articles/PMC12877362/0
2026Matrine in Liver Diseases: Mechanistic Insights and Therapeutic PotentialWen WenPMC13021390https://pmc.ncbi.nlm.nih.gov/articles/PMC13021390/0
2026Mechanism of matrine inhibiting retinoblastoma cell growth by downregulating NR1D2 to regulate phosphorylation of the PI3K/AKT signaling pathwayLi KongPMC13550455https://pmc.ncbi.nlm.nih.gov/articles/PMC13550455/0
2026Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1-Mediated DNA Damage Repair and PI3K/AKT Survival SignalingJianghao YuPMC13597169https://pmc.ncbi.nlm.nih.gov/articles/PMC13597169/0
2026Matrine induces ferroptosis and suppresses colorectal cancer through targeting the STAT3/SLC7A11 pathwayHongjie Yu42710789https://pubmed.ncbi.nlm.nih.gov/42710789/0
2025Matrine targets β-catenin and blocks the formation of β-catenin/TCF7L2 complex to promote ferroptosis and inhibit metastasis in triple-negative breast cancerYazhou Sang40651299https://pubmed.ncbi.nlm.nih.gov/40651299/0
2025The DHCR7 is the key target of lipotoxic liver injury caused by matrine through abnormal activation of the cholesterol synthesis pathwayXiaoyu Tao40250732https://pubmed.ncbi.nlm.nih.gov/40250732/0
2025Matrine in cancer therapy: antitumor mechanisms and nano-delivery strategiesDandan MengPMC12452104https://pmc.ncbi.nlm.nih.gov/articles/PMC12452104/0
2025Matrine Attenuates Neurological Deficits and Neuroinflammation by Inhibiting the HMGB1/RAGE Axis and Ferroptosis in Intracerebral Hemorrhage MicePan‐Di ChenPMC13344244https://pmc.ncbi.nlm.nih.gov/articles/PMC13344244/0
2024Matrine induces ferroptosis in cervical cancer through activation of piezo1 channelJiaqi Jin37922791https://pubmed.ncbi.nlm.nih.gov/37922791/0
2023The Promoting Role of HK II in Tumor Development and the Research Progress of Its InhibitorsKyoko Nakagawa-Goto—https://www.mdpi.com/1420-3049/29/1/750
2023Matrine exerts its neuroprotective effects by modulating multiple neuronal pathwaysSwesha Chhabra37103719https://pubmed.ncbi.nlm.nih.gov/37103719/0
2023Research Progress of Natural Matrine Compounds and Synthetic Matrine DerivativesJinlei LiPMC10421345https://pmc.ncbi.nlm.nih.gov/articles/PMC10421345/0
2023Matrine improves the hepatic microenvironment and reverses epithelial-mesenchymal transition in hepatocellular carcinoma by inhibiting the Wnt-1/β-catenin signaling pathwayJianfei ShiPMC10492086https://pmc.ncbi.nlm.nih.gov/articles/PMC10492086/0
2023Matrine disrupts Nrf2/GPX4 antioxidant system and promotes hepatocyte ferroptosisXi Wang37716422https://pubmed.ncbi.nlm.nih.gov/37716422/0
2023Matrine restrains the development of colorectal cancer through regulating the AGRN/Wnt/β-catenin pathwayXianzhe Li36620879https://pubmed.ncbi.nlm.nih.gov/36620879/0
2022Matrine alleviates spatial learning and memory impairment in diabetic mice by inhibiting endoplasmic reticulum stress and through modulation of PK2/PKRs pathwayRuyi Zhang35074478https://pubmed.ncbi.nlm.nih.gov/35074478/0
2022Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive ReviewYingda LinPMC8898013https://pmc.ncbi.nlm.nih.gov/articles/PMC8898013/0
2022Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validationPan-Ling Xu34597654https://pubmed.ncbi.nlm.nih.gov/34597654/0
2022Research progress on the pharmacological effects of matrineYanan SunPMC9469773https://pmc.ncbi.nlm.nih.gov/articles/PMC9469773/0
2021Matrine: A review of its pharmacology, pharmacokinetics, toxicity, clinical application and preparation researchesXia Li33307055https://pubmed.ncbi.nlm.nih.gov/33307055/0
2020Matrine ameliorates cognitive deficits via inhibition of microglia mediated neuroinflammation in an Alzheimer's disease mouse modelJuan Li32635978https://pubmed.ncbi.nlm.nih.gov/32635978/0
2020Matrine triggers colon cancer cell apoptosis and G0/G1 cell cycle arrest via mediation of microRNA-22Jiao Liu32072698https://pubmed.ncbi.nlm.nih.gov/32072698/0
2020Matrine: A Promising Natural Product With Various Pharmacological ActivitiesHong ZhangPMC7232545https://pmc.ncbi.nlm.nih.gov/articles/PMC7232545/0
2020Matrine induces toxicity in mouse liver cells through an ROS-dependent mechanismJie Liu32717422https://pubmed.ncbi.nlm.nih.gov/32717422/0
2020Matrine exerts anti‑breast cancer activity by mediating apoptosis and protective autophagy via the AKT/mTOR pathway in MCF‑7 cellsJikun DuPMC7533454https://pmc.ncbi.nlm.nih.gov/articles/PMC7533454/0
2020Effects of matrine in combination with cisplatin on liver cancerGaoyu HuPMC7716706https://pmc.ncbi.nlm.nih.gov/articles/PMC7716706/0
2020A Systematic Review of the Pharmacology, Toxicology and Pharmacokinetics of MatrineLongtai YouPMC7526649https://pmc.ncbi.nlm.nih.gov/articles/PMC7526649/0
2020Matrine induces apoptosis and autophagy in human lung adenocarcinoma cells via upregulation of Cavin3 and suppression of PI3K/AKT pathwayQian Wan32862598https://pubmed.ncbi.nlm.nih.gov/32862598/0
2019Matrine suppresses breast cancer metastasis by targeting ITGB1 and inhibiting epithelial-to-mesenchymal transitionLili RenPMC6909565https://pmc.ncbi.nlm.nih.gov/articles/PMC6909565/0
2019Matrine suppresses lung metastasis of human hepatocellular carcinoma by directly targeting matrix metalloproteinase-9Juyuan Zhang31126682https://pubmed.ncbi.nlm.nih.gov/31126682/0
2019Matrine induces apoptosis in acute myeloid leukemia cells by inhibiting the PI3K/Akt/mTOR signaling pathwayYanmei HaoPMC6704321https://pmc.ncbi.nlm.nih.gov/articles/PMC6704321/0
2019Matrine inhibits proliferation and promotes autophagy and apoptosis in non-small cell lung cancer cells by deactivating PI3K/AKT/mTOR pathwayYanmei HAOPMC6765564https://pmc.ncbi.nlm.nih.gov/articles/PMC6765564/0
2019Matrine Promotes Human Myeloid Leukemia Cells Apoptosis Through Warburg Effect Mediated by Hexokinase 2Guibin LinPMC6771294https://pmc.ncbi.nlm.nih.gov/articles/PMC6771294/0
2018Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial‑mesenchymal transitionYuwen WangPMC6059723https://pmc.ncbi.nlm.nih.gov/articles/PMC6059723/0
2018Matrine induces apoptosis in multiple colorectal cancer cell lines in vitro and inhibits tumour growth with minimum side effects in vivo via Bcl-2 and caspase-3Yue-Yu Gu30466620https://pubmed.ncbi.nlm.nih.gov/30466620/0
2018Matrine induces apoptosis via targeting CCR7 and enhances the effect of anticancer drugs in non-small cell lung cancer in vitroJiangtao PuPMC6830874https://pmc.ncbi.nlm.nih.gov/articles/PMC6830874/0
2017Effect of matrine against breast cancer by downregulating the vascular endothelial growth factor via the Wnt/β-catenin pathwayXu XiaoPMC5776934https://pmc.ncbi.nlm.nih.gov/articles/PMC5776934/0
2017Matrine inhibits the metastatic properties of human cervical cancer cells via downregulating the p38 signaling pathwayXiaoling Wu28677790https://pubmed.ncbi.nlm.nih.gov/28677790/0
2016Matrine improves cognitive impairment and modulates the balance of Th17/Treg cytokines in a rat model of Aβ1-42-induced Alzheimer's diseaseYanfeng ZhangPMC4737738https://pmc.ncbi.nlm.nih.gov/articles/PMC4737738/0
2016Matrine suppresses invasion of castration-resistant prostate cancer cells by downregulating MMP-2/9 via NF-κB signaling pathwayHai HuangPMC6903897https://pmc.ncbi.nlm.nih.gov/articles/PMC6903897/0
2015Effect of Matrine on HPAC cell migration by down-regulating the expression of MT1-MMP via Wnt signalingYongchao MaPMC4480578https://pmc.ncbi.nlm.nih.gov/articles/PMC4480578/0
2015Matrine induces mitochondrial apoptosis in cisplatin-resistant non-small cell lung cancer cells via suppression of β-catenin/survivin signalingHuan-Qin Wang25760455https://pubmed.ncbi.nlm.nih.gov/25760455/0
2014Matrine induces the apoptosis of lung cancer cells through downregulation of inhibitor of apoptosis proteins and the Akt signaling pathwayHuiyan Niu24969052https://pubmed.ncbi.nlm.nih.gov/24969052/0
2014Matrine reduces the proliferation and invasion of colorectal cancer cells via reducing the activity of p38 signaling pathwayHongtao Ren25348737https://pubmed.ncbi.nlm.nih.gov/25348737/0
2013Matrine induction of reactive oxygen species activates p38 leading to caspase-dependent cell apoptosis in non-small cell lung cancer cellsCaihong Tan24026034https://pubmed.ncbi.nlm.nih.gov/24026034/0
2013Matrine effectively inhibits the proliferation of breast cancer cells through a mechanism related to the NF-κB signaling pathwayHONGMIN SHAOPMC3789031https://pmc.ncbi.nlm.nih.gov/articles/PMC3789031/0
2011Meta analysis of compound matrine injection combined with cisplatin chemotherapy for advanced gastric cancerSixia Huang22375407https://pubmed.ncbi.nlm.nih.gov/22375407/0
2009Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migrationYing ZhangPMC2774570https://pmc.ncbi.nlm.nih.gov/articles/PMC2774570/0
2009Matrine induces apoptosis in gastric carcinoma cells via alteration of Fas/FasL and activation of caspase-3Zhi-jun Dai19429345https://pubmed.ncbi.nlm.nih.gov/19429345/0
2009Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signalingPengfei YuPMC2774574https://pmc.ncbi.nlm.nih.gov/articles/PMC2774574/0
2024Sodium Selenite Prevents Matrine-Induced Nephrotoxicity by Suppressing Ferroptosis via the GSH-GPX4 Antioxidant SystemXi Wang—https://pubmed.ncbi.nlm.nih.gov/38177716/0